A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies
Status:
Active, not recruiting
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered
to patients with relapsed or refractory Hematologic Malignancies
To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the
dose limited toxicities associated with HMPL-523 when administered to patients with relapsed
or refractory Hematologic Malignancies